FRONTIER BIOTECHNOLOGIES Inc.

Press Releases

   
Home>Media

Frontier Biotechnologies Partnered with XinHua Medical Products to bring revolutionary treatment for Cytomegalovirus Infection GANCIL® in China

10 November, 2023: Frontier Biotechnologies Inc. (Frontier Biotech) has partnered with Keyuan Xinhai (Beijing) Medical Products, to introduce GANCIL® (Valganciclovir Hydrochloride Tablets), a groundbreaking treatment option for cytomegalovirus (CMV) infection in China. This collaboration marks ...
  • 2023-11-14  09:22:23
details>

Aikening® New Promising Clinical Data Presented at the European AIDS Conference Preliminary Data Indicate that Aikening® Could Improve Immune Recovery Function of Immunological Non-Responders (InRs)

The 19th European AIDS Conference (EACS 2023) held in Warsaw, Poland in October 2023 witnessed a groundbreaking announcement by Frontier Biotechnologies Inc. The latest clinical trial results of Aikening®, a revolutionary treatment for people with HIV who have incomplete immune reconstitution, ...
  • 2023-11-05  09:19:40
details>

Frontier Biotechnologies Receives US FDA Clearance for Manufacturing Site Inspection

Frontier Biotechnologies is proud to announce that its wholly-owned subsidiary, Sichuan Frontier Biopharmaceutical Co., Ltd., has successfully obtained clearance from the U.S. Food & Drug Administration (FDA) for its manufacturing site inspection. This significant achievement confirms Sichuan Fr...
  • 2023-10-31  09:17:14
details>

Frontier Biotechnologies is the Award Winner of the Prestigious “24th China Patent Gold Awards"

July 21, 2023, the China National Intellectual Property Administration officially announced the list of winners awarded the “24th China Patent Awards”. Frontier Biotechnologies Inc. is awarded the Gold Award for the development of a novel HIV antiretroviral drug, which is a fusion inhibitor and a pe...
  • 2023-07-24  09:23:09
details>

Frontier Biotechnologies ranked in the list of “Top 30 Innovative Chinese Biopharmaceutical Enterprises for Small Molecule Drugs”

On June 28, 2022, Frontier Biotech (stock code "688221.SH") was ranked top 30 for the third consecutive year during the “Top 100 Innovative Chinese Biopharmaceutical Enterprises in 2022”
  • 2023-06-29  09:18:40
details>

Aikening® (albuvirtide) Granted Marketing Authorisation by the Ministry of Health in the Republic of Kazakhstan for the Treatment of HIV-1

Frontier Biotechnologies announced it obtained approval for Aikening® (albuvirtide for injection), the first long-acting fusion inhibitor treatment for HIV, from the Ministry of Health in the Republic of Kazakhstan. Aikening® is indicated to be used in combination with other antiretroviral...
  • 2023-06-09  13:38:09
details>

Aikening® (albuvirtide) Launched in Malaysia

Frontier Biotechnologies and Pahang Pharmacy have signed a partnership agreement for the supply, distribution and marketing of Aikening® in Malaysia. Aikening® is now available in Malaysia.Frontier Biotechnologies announced in September 2022 that the National Pharmaceutical Regulatory Agen...
  • 2023-03-16  09:21:15
details>

Good News | Frontier Biotech’s exclusive patented Product AIKENING® successfully renewed its contract with the National Essential Drug List

On January 18, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the National Medical Insurance, Labour Injury Insurance and Maternity Insurance Essential Drug List (2022) [hereafter referred to as the National Essential Drug List (2022...
  • 2023-01-19  13:48:02
details>

Frontier Biotech won the 2022 Biotechnology Innovation Award

On January 12, 2023, the 2nd Huaxia Health Industry Summit Forum and Golden Cane Award Ceremony, co-hosted by China Times, Lanzhou New Area Administrative Committee, was successfully held in Lanzhou. Frontier Biotech (hereinafter referred to as: the company, stock code: 688221.SH) won the "2022...
  • 2023-01-13  13:45:58
details>

Frontier Biotechnologies to Present and Update the Latest Progress of FB2001 Nebulized Aerosol Inhalation formulary at the 2022 China Pharmaceutical CMC Innovation Summit

On December 2, 2022, Dr. Min Hu, the Chief Medical Officer of Frontier Biotechnologies Inc. (the “Company”, stock code: (688221. SH) presented the latest clinical updates of COVID-19 small molecule treatment FB2001 (generic name: Bofutrelvir) for nebulized inhalation at the 2022 China Chemical Pharm...
  • 2022-12-05  09:59:48
details>

FB2001 preclinical data published at Antiviral Research

Frontier Biotechnologies (hereinafter referred to as the company, stock code: 688221. SH) announces that the preclinical data of FB2001 (generic name: Bofutrelvir), was recently published at the international peer-reviewed journal "Antiviral Research". This report highlighted the results o...
  • 2022-11-11  15:02:56
details>

Novel Inhibitor for Treating Hospitalized Patients With COVID-19

  • 2022-11-08  15:01:00
details>

Develop Innovative Therapies to Better Human Lives

Frontier Biotechnologies Inc.（Nanjing）
Medicalinfo@frontierbiotech.com
jubao@frontierbiotech.com
Adverse events report mailbox：pv@frontierbiotech.com
Copyright © 2016 Corporation All Rights ReservedFrontier Biotechnologies Inc.
Full Prescribing Information | Introduction for Use | About Frontier

This site is for informational purposes only
and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

I am a licensed Healthcare Professional I am a Patient or Caregiver